5-Fu/LV联合奥沙利铂或羟基喜树碱对胃癌辅助化疗的临床观察  

Clinical Observation of 5-Fu/LV in Combination with Oxaliplatin or HCPT for Gasitric Cancer

作　　者：程先鸣 胡长耀[2] 倪荣清 潘伟 王红民[1] 余意[1] 

机构地区：[1]汉口铁路医院肿瘤科,武汉430012 [2]华中科技大学同济医院肿瘤中心

出　　处：《肿瘤防治研究》2006年第9期679-681,共3页Cancer Research on Prevention and Treatment

摘　　要：目的比较奥沙利铂联合5-Fu／LV或羟基喜树碱联合5-Fu／LV对进展期胃癌根治切除后辅助化疗的疗效。方法79例Ⅲ期胃癌根治切除后患者接受治疗，其中Oxaliplatin＋5-Fu／LV方案（奥沙利铂组）40例，HCPT＋5-Fu／LV方案（羟基喜树碱组）39例，病人一般特征经X^2检验，两组具有可比性（P〉0．05）。结果奥沙利铂组三年生存率87．5％，羟基喜树碱组三年生存率69．2％，两组三年生存率差异有显著性（P〈0．05）。毒副反应两组Ⅰ～Ⅱ外周神经毒性有显著性差异，Oxaliplatin组为62．9％，HCPT组为31．6％（P％0．05），其他毒副反应的差异无显著性（P〉0.05）。结论奥沙利铂联合5-Fu／LV对Ⅲ期胃癌术后辅助化疗效果确切，毒副反应可耐受，不失为进展期胃癌根治切除后辅助化疗的较好选择。Objective To compare the novel neoadjuvant approach of Oxaliplatin and 5-Fu/LV with the approach of HCPT and 5-Fu/LV for patients with advanced gastric carcinoma excised completely, and evaluate the 3-year livability and the adverse reaction. Methods 79 patients suffered gastric carcinoma excised accepted the treatment. Among those, 40 were treated by the approach of Oxaliplatin and 5-Fu/ LV. 39 were treated by the approach of HCPT and 5-Fu/LV. The patients statistic characters were tested by X^2 These two groups are comparable （P〉0. 05）. Results 3-year livability of Oxaliplatin groups is 87. 5 percent,3 year livability between the two groups is obvious （P〈0. 05）. The diversity of the two groups＇ （ Ⅰ , Ⅱ） perisensory nerve toxicity is also obvious. 62. 9 percent toxicity group and 31.6 percent of HCPT group appear the toxicity （P〈0. 05）, but the diversity of adverse reaction is not obvious （P〉 0. 05）. Conclusion The effect of combined treatment by Oxaliplatin and 5 Fu/LV for patients with phase Ⅲ gastric carcinoma excised is definite. The adverse reaction can be refracted. It is a better choice to use Oxaliplatin and 5-Fu/LV for patients with advanced gastric carcinoma excised as a novel neoadju vant approach.

关 键 词：胃癌 奥沙利铂 羟基喜树碱 5-FU/LV 

分 类 号：R735.2[医药卫生—肿瘤]